Establishment and serial passage of cell cultures derived from LuCaP xenografts

Prostate

Volumn 73, Issue 12, 2013, Pages 1251-1262

  Young, Sarah R ^a   Saar, Matthias ^a   Santos, Jennifer ^a   Nguyen, Holly M ^b   Vessella, Robert L ^b,c   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Puget Sound VA Health Care System   (United States)

Author keywords

preclinical model; prostate cancer; spheroids

Indexed keywords

ANDROGEN; COLLAGENASE; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER RESEARCH; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CRYOPRESERVATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LUCAP XENOGRAFT; MYCOPLASMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUSPENSION CELL CULTURE; THAWING; TUMOR SPHEROID; TUMOR XENOGRAFT; VIRUS CULTURE;

PRECLINICAL MODEL; PROSTATE CANCER; SPHEROIDS;

ANIMALS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; SERIAL PASSAGE; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881050308     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22610     Document Type: Article

References (29)

1. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL,. The current state of preclinical prostate cancer animal models. Prostate 2008; 68 (6): 629-639.
2. Sobel RE, Sadar MD,. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1. J Urol 2005; 173 (2): 342-359.
3. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM,. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3 (72): 72ra 17.
4. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM,. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19 (5): 664-678.
5. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A,. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1 (6-7): 315-322.
6. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR,. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120 (8): 2715-2730.
7. van Weerden WM, Bangma C, de Wit R,. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer 2009; 100 (1): 13-18.
8. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA,. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66 (17): 8337-8341.
9. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T,. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67 (13): 6130-6135.
10. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L,. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res 2012; 72 (2): 527-536.
11. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL,. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 2003; 55 (4): 239-246.
12. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, Lange PH,. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996; 2 (6): 1039-1048.
13. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R,. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol 2002; 161 (2): 705-715.
14. Peehl DM,. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005; 12 (1): 19-47.
15. Tomayko MM, Reynolds CP,. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24 (3): 148-154.
16. Xu Y, Zhu X, Hahm HS, Wei W, Hao E, Hayek A, Ding S,. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc Natl Acad Sci USA 2010; 107 (18): 8129-8134.
17. Korenchuk S, Lehr JE, MC, L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ,. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001; 15 (2): 163-168.
18. Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H, Tsujii M, Ohue M, Inoue M,. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci USA 2011; 108 (15): 6235-6240.
19. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J,. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 2011; 108 (41): 17087-17092.
20. Cory AH, Owen TC, Barltrop JA, Cory JG,. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991; 3 (7): 207-212.
21. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL,. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010; 70 (16): 1799-1808.
22. Chatterjee R,. Cell biology. Cases of mistaken identity. Science 2007; 315 (5814): 928-931.
23. (NIH). NIOH. NOT-OD-08-017: Notice Regarding Authentication of Cultured Cell Lines. 2007.
24. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KL, Debenham PG,. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001; 98 (14): 8012-8017.
25. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, Huang J, Witte ON,. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc 2011; 6 (5): 656-667.
26. Chen S, Principessa L, Isaacs JT,. Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate 2012; 72 (13): 1478-1489.
27. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, Haddad BR, Rhim JS, Dritschilo A, Riegel A, McBride A, Schlegel R,. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180 (2): 599-607.
28. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R,. The use of 3-D cultures for high-throughput screening: The multicellular spheroid model. J Biomol Screen 2004; 9 (4): 273-285.
29. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S,. High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. Analyst 2011; 136 (3): 473-478.